{"type":"trials","record":{"id":396,"source_id":"clinicaltrials-gov","external_id":"NCT06948149","title":"Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment","brief_summary":"The goal of this 26-week trial is to learn if creatine supplementation and resistance training (i.e., weightlifting; exercise that increases muscle mass), alone and together, impact cognition, brain health, and physical function in older adults with mild cognitive impairment. Previous studies have shown that resistance training improves cognition and brain health in older adults. Creatine is naturally occurring in the human body and is known to decline with age. Studies have shown that creatine increases muscle mass and bone density in older adults when supplemented. Some research has suggested that creatine may also improve cognition and brain health. However, little is known about how creatine supplementation affects the aging brain and body alone and when combined with resistance training, especially in those with known cognitive impairment. In this study, participants will be randomly assigned to one of four groups: 1) creatine and resistance training, 2) placebo and resistance training, 3) creatine and active control (balance and tone classes), or 4) placebo and active control. Participants in the creatine groups will take creatine every day during the study. Participants in the placebo groups will take a look-alike substance that contains no drug every day during the study. Participants in the resistance training groups will attend three 60-minute classes per week that target each major muscle group and will increase in difficulty during the study. Participants in the active control group will attend three 60-minute classes per week that will consist of balance, stretching, and range of motion exercises. This group accounts for variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation. Researchers will collect information before and after the 26 weeks to see if creatine supplementation and/or resistance training have any effects on cognition, brain health, and/or physical function. The investigators suspect that both creatine supplementation and resistance training will improve cognition, brain health, and physical function alone. However, it is thought that the combination of creatine supplementation and resistance training will improve cognition, brain health, and physical function more.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Western University, Canada","enrollment":140,"countries":["Canada"],"start_date":"2026-01-01","completion_date":"2027-12-01","last_update_date":"2026-08-20","source_url":"https://clinicaltrials.gov/study/NCT06948149","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:45:04.314999+00:00","last_seen_at":"2026-09-25T07:05:20.248+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years","comparator":"Placebo supplementation and active control group","organization":"Western University, Canada","interventions":["Creatine monohydrate","Resistance training"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Corsi Span - Corsi Block Tapping Task — Baseline and 26 weeks","Reaction Time - Corsi Block Tapping Task — Baseline and 26 weeks","Interference Score - Stroop Task — Baseline and 26 weeks","Span Capacity - Digits Forward and Backward Subtests — Baseline and 26 weeks","Time - Trail Making Test (Part B) — Baseline and 26 weeks","Memory Score - Rey Auditory Verbal Learning Test — Baseline and 26 weeks","Time - Timed Up & Go (TUG) Test — Baseline and 26 weeks","Short Physical Performance Battery (SPPB) Score — Baseline and 26 weeks","Number of Falls - Falls History and Prospective Reporting — Baseline, 26 weeks, and when they occur","Estimated One Repetition Maximum (E1RM) - Muscle Strength — Baseline, midpoint, and 26 weeks","Grip Strength — Baseline and 26 weeks","Bone Density — Baseline and 26 weeks","Biomarker Concentration - Phosphorylated Tau 217 (p tau 217) — Baseline and 26 weeks","Biomarker Concentration - Neurofilament Light Chain (NfL) — Baseline and 26 weeks","Biomarker Concentration - Glial Fibrillary Acidic Protein (GFAP) — Baseline and 26 weeks","Biomarker Concentration - Amyloid Beta 42 (Aβ42) — Baseline and 26 weeks","Biomarker Concentration - Creatinine — Baseline and 26 weeks","Biomarker Concentration - Brain-Derived Neurotrophic Factor (BDNF) — Baseline and 26 weeks","Biomarker Concentration - Insulin-like Growth Factor 1 (IGF-1) — Baseline and 26 weeks","Biomarker Concentration - Interleukin 6 (IL-6) — Baseline and 26 weeks"],"design_description":"RANDOMIZED · FACTORIAL · SUPPORTIVE CARE · TRIPLE","source_has_results":false},"controlled_terms":["Creatine","Exercise","Mild Cognitive Impairment (MCI)","Creatine monohydrate","Resistance training"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: resistance training.","quality_checked_at":"2026-09-25T07:05:30.295959+00:00","duplicate_cluster_key":"id:nct06948149","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-01-01 to 2027-12-01","comparator":"Placebo supplementation and active control group","confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T07:05:20.257Z","intervention":["Creatine monohydrate","Resistance training"],"participants":140,"study_design":"RANDOMIZED · FACTORIAL · SUPPORTIVE CARE · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Corsi Span - Corsi Block Tapping Task — Baseline and 26 weeks","Reaction Time - Corsi Block Tapping Task — Baseline and 26 weeks","Interference Score - Stroop Task — Baseline and 26 weeks","Span Capacity - Digits Forward and Backward Subtests — Baseline and 26 weeks","Time - Trail Making Test (Part B) — Baseline and 26 weeks","Memory Score - Rey Auditory Verbal Learning Test — Baseline and 26 weeks","Time - Timed Up & Go (TUG) Test — Baseline and 26 weeks","Short Physical Performance Battery (SPPB) Score — Baseline and 26 weeks","Number of Falls - Falls History and Prospective Reporting — Baseline, 26 weeks, and when they occur","Estimated One Repetition Maximum (E1RM) - Muscle Strength — Baseline, midpoint, and 26 weeks","Grip Strength — Baseline and 26 weeks","Bone Density — Baseline and 26 weeks","Biomarker Concentration - Phosphorylated Tau 217 (p tau 217) — Baseline and 26 weeks","Biomarker Concentration - Neurofilament Light Chain (NfL) — Baseline and 26 weeks","Biomarker Concentration - Glial Fibrillary Acidic Protein (GFAP) — Baseline and 26 weeks","Biomarker Concentration - Amyloid Beta 42 (Aβ42) — Baseline and 26 weeks","Biomarker Concentration - Creatinine — Baseline and 26 weeks","Biomarker Concentration - Brain-Derived Neurotrophic Factor (BDNF) — Baseline and 26 weeks","Biomarker Concentration - Insulin-like Growth Factor 1 (IGF-1) — Baseline and 26 weeks","Biomarker Concentration - Interleukin 6 (IL-6) — Baseline and 26 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"resistance-training","is_published":true,"match_reasons":["Title contains controlled term: resistance training.","Abstract contains controlled term: resistance training.","Source terminology contains: resistance training.","Title supplies longevity context: older adult.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Resistance training","slug":"resistance-training"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/396","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}